Immutep Ltd has released a press release.
Immuteps partner, EOC Pharma, expands efti trial pipeline
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Immutep
- Chinese patent granted for anti-LAG-3 antibody LAG525
- INSIGHT-003 investigator-initiated trial - 1st patient dosed
- Completion of Placement - Tranche 2
- Completion of Share Purchase Plan
- US FDA & IRB approves start of ph2b head & neck cancer trial
Later from Immutep
- Recruitment of patients completed for Part B of TACTI-002
- Immutep Receives A$3.4 million R&D French Tax Incentive
- Immutep Quarterly Activities Report & Appendix 4C
- Immutep receives EMA scientific advice for Phase 3 in MBC
- Immutep granted Chinese Patent for eftilagimod alpha
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep